Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc.verified

HOWL

Price:

$2.13

Market Cap:

$93.09M

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company...[Read more]

Industry

Biotechnology

IPO Date

2021-04-30

Stock Exchange

NASDAQ

Ticker

HOWL

The Enterprise Value as of September 2024 (TTM) for Werewolf Therapeutics, Inc. (HOWL) is -5541314.00

According to Werewolf Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -5541314.00. This represents a change of -109.30% compared to the average of 59.59M of the last 4 quarters.

Werewolf Therapeutics, Inc. (HOWL) Historical Enterprise Value (quarterly & annually)

How has HOWL Enterprise Value performed in the past?

The mean historical Enterprise Value of Werewolf Therapeutics, Inc. over the last ten years is 200.27M. The current -5541314.00 Enterprise Value has changed -376.69% with respect to the historical average. Over the past ten years (40 quarters), HOWL's Enterprise Value was at its highest in in the March 2021 quarter at 341.04M. The Enterprise Value was at its lowest in in the December 2022 quarter at -51624250.00.

Quarterly (TTM)
Annual

Average

200.27M

Median

183.43M

Minimum

-55459800.00

Maximum

446.74M

Werewolf Therapeutics, Inc. (HOWL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Werewolf Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual Enterprise Value = 446.74M

Minimum Annual Increase = -199.49%

Minimum Annual Enterprise Value = -55459800.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202355.18M-199.49%
2022-55459800.00-130.24%
2021183.43M-50.62%
2020371.47M-16.85%

Werewolf Therapeutics, Inc. (HOWL) Average Enterprise Value

How has HOWL Enterprise Value performed in the past?

The current Enterprise Value of Werewolf Therapeutics, Inc. (HOWL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

61.05M

5-year avg

200.27M

10-year avg

200.27M

Werewolf Therapeutics, Inc. (HOWL) Enterprise Value vs. Peers

How is HOWL’s Enterprise Value compared to its peers?

Werewolf Therapeutics, Inc.’s Enterprise Value is less than Monte Rosa Therapeutics, Inc. (279.81M), less than Design Therapeutics, Inc. (272.37M), less than Ikena Oncology, Inc. (47.83M), less than Stoke Therapeutics, Inc. (589.89M), less than Edgewise Therapeutics, Inc. (1.53B), less than Decibel Therapeutics, Inc. (96.42M), less than Celcuity Inc. (625.58M), less than C4 Therapeutics, Inc. (434.14M), less than Talaris Therapeutics, Inc. (50.00M), greater than Adicet Bio, Inc. (-82159510.00), less than Cullinan Oncology, Inc. (866.65M), less than Vor Biopharma Inc. (27.51M), less than Third Harmonic Bio, Inc. (281.30M), less than Passage Bio, Inc. (46.47M), less than Acrivon Therapeutics, Inc. Common Stock (221.17M), less than Eliem Therapeutics, Inc. (330.21M), greater than Molecular Partners AG (-9821016.18), less than MediciNova, Inc. (45.42M), less than Anebulo Pharmaceuticals, Inc. (49.05M), less than Champions Oncology, Inc. (72.75M), greater than Cyteir Therapeutics, Inc. (-20511738.00),

Build a custom stock screener for Werewolf Therapeutics, Inc. (HOWL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Werewolf Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Werewolf Therapeutics, Inc. (HOWL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Werewolf Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Werewolf Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Werewolf Therapeutics, Inc. (HOWL)?

What is the 3-year average Enterprise Value for Werewolf Therapeutics, Inc. (HOWL)?

What is the 5-year average Enterprise Value for Werewolf Therapeutics, Inc. (HOWL)?

How does the current Enterprise Value for Werewolf Therapeutics, Inc. (HOWL) compare to its historical average?